PRRS Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

PRRS Vaccine Market

The future of the global prrs vaccine market looks promising with opportunities in the government tender and market sales markets. The global prrs vaccine market is expected to reach an estimated $2 billion by 2035 from $1 billion in 2027 with a CAGR of 5.9% from 2027 to 2035. The major drivers for this market are the rising global demand for disease prevention and the advancements in vaccine technology.

• Lucintel forecasts that, within the type category, killed vaccines is expected to witness higher growth over the forecast period due to killed vaccines have a larger market size due to their safety, stability, and ease of storage, making them more suitable for widespread use.
• Within the application category, government tender is expected to witness the higher growth due to government tender is larger due to bulk procurement.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the large swine commercial industry and the robust veterinary healthcare infrastructure.

Emerging Trends in PRRS Vaccine Market

Between 2025 and 2027, the prrs vaccine market shifts from conventional herd protection toward customized solutions driven by data. Swine producers are looking for vaccines specific to the circulating viral strains and that eliminate production loses and complement regional control programs. Lucintel predicts that swine populations and biosecurity, along with the availability of vaccination platforms, will create considerable disparities across major global swine producing regions.

• Challenging The Supply of Specific Strain Vaccines in 2025: There was the need to match PRRSV lineages that were monitored in different regions and sequenced in the field. Most vaccine products continued to be of the modified live type since they both reduced the severity of disease and infection. In the next three to five years, improved antigen matching will influence purchasing decisions.
• The Gearing Platforms in 2025-2027 Continued: To evaluate the use of recombinant, vector, and subunit vaccine approaches, while mRNA vaccine design started to gain focus of veterinary vaccine research and investment. Improved safety and ease of modification will introduce a range of alternatives beyond traditional live products.
• Integrators of Swine Continued: To expand their electronic health records and laboratory dashboards. This also linked vaccination with mortality, feed conversion, and reproductive data. Suppliers will need to demonstrate measurable data outcomes of herd management.
• The Four Major Swine-producing Regions: In China, Europe, Brazil and the USA continued to employ different surveillance and vaccination protocols. This continues to reflect different production systems and different pressures. Regional differentiation will sustain local formulations and tech services as compared to one unified product.
• Integrated Biosecurity: Controlling PRRS with vaccinations and combinatorial approaches to transportation, screening of replacement stock, and on-farm diagnostics and tests is increasingly popular. The U.S. Secure Pork Supply serves as a framework for continuing integration. This integrated model is expected to continually create the need for vaccinations because producers will not fully mitigate the risk of the disease by vaccinating.

The prrs vaccine market will continue to grow, even with steady sales. Growth will be primarily driven by the improvement of herd economics. Suppliers integrating surveillance and diagnostics with vaccines and providing additional services will benefit from customer loyalty. Competition will remain strong, particularly, with many companies offering generic modified-live vaccines. Future leaders in the market will be those companies that develop vaccines for local strains quickly and with ease of use

Recent Developments in the PRRS Vaccine Market

From 2025 to 2027, PRRS vaccine activities will increase due to the need for more control over reproduction, faster herd recovery, and less reliance on the use of antibiotics. Lucintel will base their estimations on the growth of swine commercial inventories, approvals of vaccines, and how unique the vaccines will be compared to the other vaccines. There will be an increased investment for regional manufacturing of vaccines, gene-based surveillance, and the circulation of complex viruses.

• New Product Approvals: Regulatory agencies will start to allow access to new, more up to date strains of PRRS vaccines (2025) which will allow for greater options and more competition against strain coverage, safety, and the duration of the vaccines' efficacy.
• Increased Production: Vaccine manufacturers are moving to increase biological production to avoid stopping the supply of vaccines due to high demand in swine dense regions (2025). Increased capacity will ensure reliable supply of vaccines and help support the increasing demand of herd health programs.
• Surveillance Partnerships: There are collaborations between some diagnostics companies, veterinary labs, and sequencing services to offer vaccination programs, and some services are processing more than 10,000 samples in a year (2025). The goal is to provide better coverage for strain variability and increase demand for vaccines based on local strains.
• Digital Herd Health: Vaccine manufacturers are connecting their vaccination records to cloud based systems with the capability to reach over 10,000 farms (2026). This will allow for performance of vaccines on a herd basis, and support a recurring sales model.
• Regional Commercialization: Suppliers are applying for approvals, and partnership agreements to cover Asia and Latin America to provide coverage for the major swine production areas of China and Brazil (2025). This will decrease the dependency on the more established markets and regions within North America and Europe, and increase local demand.

PRRS vaccine market growth will not be based on simple dose sales growth. More substantial results will need to be seen for producers to buy more. Lowered mortality and improved reproductive rates will need to be seen along with proof that the vaccine is suited to the local viruses. Strong field data and manufacturing combined with a flexible regulatory unit will lead to a higher market share. Price will continue to be important, but the cost of an outbreak will make reliability the stronger selling aspect.

Strategic Growth Opportunities in the PRRS Vaccine Market

The prrs vaccine market is beginning to gain substantial traction as producers address circulating strains, more restrictive antibiotics, and varying herd health. For the 2024-2026 time frame, more advanced diagnostics and an increased focus on regional vaccinations with consolidation of integrators will alter purchasing. In line with this shift, the Lucintel market outlook incorporates moving from a focus on selling products to controlling and managing the impact of assessed diseases through continuous, ongoing support.

• Regional Strain-matched Vaccines: China had 408.8 million pigs in March 2025 creating demand for regional vaccines. In the next 3-5 years, producers will focus on regional vaccinations with the growing rejection of broad, unmatched programs.
• Integrated Diagnostics and Vaccinations: In January 2025, the USDA reported more than 6.2 million diagnostic tests under its swine health programs. Selecting vaccinations based on testing will provide continuous, recurring revenue based on the tested herd.
• Premium Vaccines for High-health Herds: Per the FAO 2025 survey, high health breeding systems can be expected to support increased pricing for vaccines.
• Growth in Swine Regions: Vietnam estimated its pig herd at 25.5 million in June 2025. Vaccine suppliers will be drawn to the region as demand for more advanced biosecurity, technical services, and improved vaccines will come with increased commercial farms.
• Digital Herd-health Services: In 2025, large producers began to record vaccination and mortality data for thousands of sows. Suppliers will be able to justify renewing subscriptions for digital services and remote veterinary support.

Suppliers of PRRS vaccine should prioritize measurable herd results over dose volume. The most significant revenue opportunities will come from strain matching, integrated diagnostics, and documenting reduction in mortality or improvements in reproductive performance. Regulatory control is very important, particularly for modified-live products. Companies that integrate field evidence together with reliable supply can justify higher prices and can enter production systems that are underequipped before 2030.

PRRS Vaccine Market Drivers and Challenges

The development of the prrs vaccine market depends on the prevalence of the disease, the changes in pork production systems, the production of new vaccines, and modifications in the regulatory environment concerning farm animals. The economic situation, the priorities of biosecurity and sustainability, and the adoption of the market also depend on these factors. According to Lucintel, technology and production efficiency, and regional disease control strategies, among others, are other important market drivers. Constraints include efficacy, costs, and regulation, among others.

The factors responsible for driving this market include :

• Increased Disease Incidence: The continued loss of reproductive performance, piglet survival, and farm productivity due to porcine reproductive and respiratory syndrome stimulates farmers to enhance Prevention programs. The USDA reports that in February 2025, the USA had over 75.9 million hogs and pigs, illustrating the economic risk of production loses. In the next 3 to 5 years, PRRS demand for preventive vaccination will remain high due to expanding herds and persistent virus circulation in the population.
• Evolving Technology: The safety and ease of adoption of vaccination programs have also improved due to advancements in modified live and inactivated vaccines as well as next generation technologies. In 2025, research continued on next generation gene and vectored vaccine technologies. Over the next 3 to 5 years, improved field efficacy of data-driven vaccination programs and better antigen selection and diagnostics will encourage adoption of improved protection against the negative consequences of PRRS infection regardless of production system.
• Expansion of Commercial Pork Production: The growing demand for pork and the growth of intensive farming have made herd health more important economically. In 2025, world pork production was over 120 million metric tons. The demand for prevention of diseases in breeding, nursery, and finishing herds continues. In the next 3-5 years, larger integrated farms are expected to standardize illness prevention vaccinations because illness outbreaks can adversely affect animal welfare and planning of labor supply, and very negatively impact the planned profitability of the whole production system.
• Government and Industry Disease-control Programs: With regional surveillance and initiatives to eradicate disease in conjunction with biosecurity, producers are more inclined to use vaccines in their control strategies. January 2025 reported a continued thrust by veterinary services and swine organizations in major producing areas, on farm-based biosecurity, disease testing, and movement control. In the next 3-5 years, improvement in the public and private partnership and the recommendation of vaccination in high risk areas should provide much needed assurance and confidence in vaccinations in high risk areas.
• Economic and Sustainability Benefits: Vaccinations are expected to reduce mortality, and increase feed efficiency and reproductive efficiency. 2025 was a difficult year for many producers, due to the cost of feed, energy and labor. Vaccine use is expected to increase in the next 3-5 years.

The challenges facing this market include:

• Variable Efficacy and Viral Diversity: Rapidly evolving PRRS viruses may mean vaccination may not provide full protection against all the existing strains. In 2025, producers continued to encounter regional variations in virus lineages, herd immunity, and vaccine response resulting in a lack of consistency on different farms. In the next three to five years, rapid changes in antigenicity, maternal immunity, and incomplete cross-protection will create challenges in product selection and may require multiple tests, more updated formulations, and combined tests, which will increase the level of difficulty and create a lack of confidence in product selection.
• Regulatory and Safety Issues: Safety, efficacy, and manufacturing consistency of the vaccine in all types of animals must be proven for approval. In 2025, regulatory issues were the most important for modified-live and genetically engineered vaccines due to concerns associated with reversion, shedding, differentiation of vaccinated vs. infected animals, and concerns related to international trade. In the next three to five years, longer approval times due to different standards in different countries will slow the introduction of improved products, increase the cost of manufacturing, and restrict the use of improved products in developing countries.
• High Adoption Costs and Implementation Barriers: Implementing a vaccination program requires purchasing the product, labor, cold-chain management, records, and other biosecurity measures. In 2025, smaller farms and producers in price-sensitive regions remained vulnerable to budget constraints and uneven veterinary service. In the next three to five years, inflation, uncertain pork prices, and insufficient technology may all reduce the rate of adoption. Producers will demand evidence of return on investment.

The market for pigs infected with porcine reproductive and respiratory syndrome (prrs) vaccine will grow as customers recognize the need for vaccines for long-term sustainable and profitable pork production. Concurrent with the adoption of the technology will be large-scale operations, favorable programs, and economic conditions. Variable protection and delays in vaccine approval and the subsequent implementation will limit the market. The more innovative vaccines, coupled with better surveillance, rugged vaccine delivery systems, and integrated biosecurity based on regional production conditions, will lead the market.

List of PRRS Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies prrs vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prrs vaccine market companies profiled in this report include-

• CAHIC
• Merial
• MSD Animal Health
• Chopper Biology
• Ceva
• Chengdu Tecbond
• Veterinary
• Ringpu Biology
• Qilu Animal Health
• DHN

PRRS Vaccine Market by Segment

The study includes a forecast for the global prrs vaccine market by type, application, and region.

PRRS Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Live Vaccines
• Killed Vaccines

PRRS Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• Government Tender
• Market Sales

PRRS Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the PRRS Vaccine Market

The prrs vaccine market is evolving with tighter disease-control policies, growing domestic biomanufacturing and more gene-sequenced vaccines. Lucintel forecasts that from 2025 to 2027 supply reliability and technology adoption will be driven by regulations, investments, and more partnerships. They expect changes will be significant enough to warrant careful evaluation.

• United States: Modern regulations combined with producer-funded biosecurity initiatives are facilitating vaccine deployment. The USDA APHIS reported 2,500 confirmed swine premises within its disease-surveillance system in March 2025. The next three to five years will create increased demand for differentiated vaccines, diagnostics and coordinated herd management.
• China: The Ministry of Agriculture and Rural Affairs continued approval and oversight of PRRS and domestic vaccine manufacturers continued their research on both recombinant and attenuated vaccines. In June 2025, China's swine inventory was around 408 million head. The large production base will encourage domestic manufacturing and more rapid replacement of existing technologies.
• Germany: Boehringer Ingelheim continued marketing its ReproCyc PRRS EU platform and continued expansion of veterinary biologics within Europe. Germany had an estimated €1.3 billion export of pharmaceuticals in January 2025. Germany's manufacturing and regulations will determine the regional availability of high-value PRRS vaccines.
• India: Indian veterinary institutes and manufacturers continued work on locally appropriate PRRS vaccines. The government continued to fund the National Animal Disease Control Program. The outlay is ₹13,343 crore. These initiatives will create more capacity and provide a better base for commercial pig production.
• Japan: Japan has kept rigid import and animal health controls while MSD Animal Health and other suppliers have continued providing licensed PRRS vaccines. Japan had approximately 8.8 million pigs in February 2025. Policymakers will continue to rely on regulated imported products and will impact licensing, partnerships, and supply chain decisions well into 2030.

Features of the Global PRRS Vaccine Market

• Market Size Estimates: prrs vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: prrs vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: prrs vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the prrs vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prrs vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the prrs vaccine market by type (live vaccines and killed vaccines), application (government tender and market sales), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?